CDT Equity (NASDAQ:CDT) Trading Down 4.7% – Time to Sell?

Posted by Alanna Baker on Feb 6th, 2026

CDT Equity Inc. (NASDAQ:CDT – Get Free Report) shares dropped 4.7% during mid-day trading on Thursday . The company traded as low as $0.9110 and last traded at $1.01. Approximately 246,378 shares were traded during trading, a decline of 79% from the average daily volume of 1,186,239 shares. The stock had previously closed at $1.06.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Read Our Latest Stock Report on CDT Equity

CDT Equity Price Performance

The stock has a market capitalization of $1.65 million, a price-to-earnings ratio of 0.00 and a beta of 1.80. The firm’s fifty day moving average is $1.48 and its 200-day moving average is $5.40.

CDT Equity (NASDAQ:CDT – Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($13.16) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CDT Equity stock. Apollon Wealth Management LLC bought a new stake in shares of CDT Equity Inc. (NASDAQ:CDT – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 107,454 shares of the company’s stock, valued at approximately $73,000. Apollon Wealth Management LLC owned about 28.28% of CDT Equity at the end of the most recent quarter. Institutional investors and hedge funds own 3.29% of the company’s stock.

About CDT Equity

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.